A clinical formulation indicated for Oncology Support. Facilitates the inhibition of specific kinases to limit tumor cell growth and support established therapeutic pathways.
Formulated to alleviate tumor growth and address vascularization to support clinical stability and mitigate disease progression in advanced liver, kidney, or thyroid cancers.
Mechanism of Action
Sorafenib inhibits multiple enzymes called kinases that are involved in both the growth of cancer cells and the development of new blood vessels (angiogenesis) that supply the tumor, effectively starving and slowing the cancer.
Route of Administration
Oral
Onset Time
Steady state in 7 days
Duration
12–24 hours
Contraindications
Hypersensitivity to sorafenib, Severe hepatic impairment (Child-Pugh C), Pregnancy
Severe Adverse Events
Heart attack (myocardial ischemia), Severe bleeding, Gastrointestinal perforation, Severe skin reactions, Hepatitis
Information for Nexavar is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
